NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.17 -0.50 (-4.28 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$11.17
Today's Range$11.04 - $11.56
52-Week Range$7.46 - $18.00
Volume98,109 shs
Average Volume98,434 shs
Market Capitalization$222.84 million
P/E Ratio-2.30
Dividend YieldN/A
Beta1.55
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIGR
Previous Symbol
CUSIPN/A
Phone650-272-6138

Debt

Debt-to-Equity Ratio0.56
Current Ratio4.59
Quick Ratio4.59

Price-To-Earnings

Trailing P/E Ratio-2.30
Forward P/E Ratio-3.11
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.14 per share
Price / Book5.22

Profitability

EPS (Most Recent Fiscal Year)($4.86)
Net Income$-42,440,000.00
Net MarginsN/A
Return on Equity-155.57%
Return on Assets-85.14%

Miscellaneous

Employees16
Outstanding Shares19,090,000
Market Cap$222.84 million
OptionableNot Optionable

Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) announced its quarterly earnings data on Friday, November, 9th. The biotechnology company reported ($1.20) EPS for the quarter, missing the Zacks' consensus estimate of ($0.77) by $0.43. View Eiger Biopharmaceuticals' Earnings History.

When is Eiger Biopharmaceuticals' next earnings date?

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Eiger Biopharmaceuticals.

What price target have analysts set for EIGR?

6 brokerages have issued twelve-month price objectives for Eiger Biopharmaceuticals' shares. Their forecasts range from $24.00 to $55.00. On average, they anticipate Eiger Biopharmaceuticals' stock price to reach $32.6667 in the next twelve months. This suggests a possible upside of 192.5% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.

What is the consensus analysts' recommendation for Eiger Biopharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

Headlines about EIGR stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of Eiger Biopharmaceuticals' key competitors?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the folowing people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 54)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 55)
  • Mr. James A. Welch, Chief Financial Officer (Age 60)
  • Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 53)
  • Mr. James P. Shaffer, Chief Bus. Officer (Age 51)

Who are Eiger Biopharmaceuticals' major shareholders?

Eiger Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (8.88%), Vanguard Group Inc. (2.36%), Vanguard Group Inc (2.36%), Prosight Management LP (2.40%), Renaissance Technologies LLC (1.96%) and BlackRock Inc. (1.58%). Company insiders that own Eiger Biopharmaceuticals stock include Eldon C Mayer III, Interwest Partners X Lp, Jeffrey S Glenn, Joanne Quan and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

Which institutional investors are selling Eiger Biopharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP and P.A.W. Capital Corp. Company insiders that have sold Eiger Biopharmaceuticals company stock in the last year include Interwest Partners X Lp and Joanne Quan. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Which institutional investors are buying Eiger Biopharmaceuticals stock?

EIGR stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Renaissance Technologies LLC, Algert Global LLC, JPMorgan Chase & Co., Acadian Asset Management LLC, Vanguard Group Inc, Vanguard Group Inc. and Tocqueville Asset Management L.P.. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn and Thomas John Dietz. View Insider Buying and Selling for Eiger Biopharmaceuticals.

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $11.17.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $222.84 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.

What is Eiger Biopharmaceuticals' official website?

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]


MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel